Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NC-6300: Ph I data

An open-label, Japanese Phase I trial in 19 patients with advanced or recurrent malignant solid tumors either refractory

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE